Article
FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
Minerva medica - 1 Oct 2020
Mosquera Orgueira Adrián, Bao Pérez Laura, Mosquera Torre Alicia, Peleteiro Raíndo Andrés, Cid López Miguel, Díaz Arias José Á, Ferreiro Ferro Roi, Antelo Rodríguez Beatriz, González Pérez Marta S, Albors Ferreiro Manuel, Alonso Vence Natalia, Pérez Encinas Manuel M, Bello López José L, Martinelli Giovanni, Cerchione Claudio
Abstract excerpt
Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene arise in 25-30% of all acute myeloid leukemia (AML) patients. These mutations lead to constitutive activation of the protein product and are divided in two broad types: internal tandem duplication (ITD) of the juxtamembrane domain (25% of cases) and point mutations in the tyrosine kinase domain (TKD). Patients with FLT3 ITD mutations have a high relapse risk...
Topics
- Aniline Compounds
- Antineoplastic Agents
- Benzimidazoles
- Benzothiazoles
- Carbazoles
- Drug Resistance, Multiple
- Drug Resistance, Neoplasm
- Forecasting
- Furans